Eli Lilly and Co. has acquired two investigational PET imaging agents from Siemens Healthcare in an effort to boost its commitment to Alzheimer’s disease research and development. Both tracers have been clinically proven to selectively target neurofibrillary tangles (NFTS), or tau, a diagnostic biomarker for Alzheimer’s disease. To read more of this article….